Functional Living Index Cancer (FLIC)

Abstract

The Functional Living Index – Cancer (FLIC) is a landmark 22-item, self-administered multidimensional patient-reported outcome measure (PROM) specifically developed to assess health-related quality of life (HRQoL) in adult cancer patients. Introduced by Harvey Schipper and colleagues in 1984, the instrument was conceived to overcome the limitations of purely clinician-rated performance scales, such as the Karnofsky Performance Scale, by capturing the patient’s subjective appraisal of their disease and treatment impact. The FLIC evaluates five core latent dimensions: physical and somatic functioning, psychological and emotional well-being, household and vocational role performance, social and interpersonal integration, and cancer- or treatment-specific symptoms (principally nausea and pain). Responses are gathered along a 7-point modified visual analogue scale (VAS) featuring distinct semantic anchors tailored to each item. Composite scores range from 22 to 154, with higher cumulative values denoting superior functional living and heightened quality of life. Ten of the twenty-two items require reverse-scoring to counter response acquiescence. Extensive psychometric validation studies across international oncological cohorts confirm high internal consistency (Cronbach’s alpha typically ranging from .88 to .93), commendable test–retest reproducibility ($r = .85$ to $.90$), and robust convergent and construct validity with concurrent indices such as the EORTC QLQ-C30, the Medical Outcomes Study 36-Item Short Form (SF-36), and psychiatric inventories measuring anxiety and depression. This article provides an exhaustive psychometric review of the FLIC, including its theoretical architecture, measurement validity, underlying factorial topology, scoring algorithms, and clinical implementation parameters.

Keywords

Functional Living Index Cancer, FLIC, oncology psychometrics, health-related quality of life, patient-reported outcome measures, cancer clinical trials, functional status, psychological distress, symptom burden, cancer survival prediction

Authors

The Functional Living Index – Cancer was formulated and psychometrically standardized by a multidisciplinary team of medical oncologists, biostatisticians, and behavioral scientists at the University of Manitoba and the St. Boniface General Hospital Research Centre in Winnipeg, Manitoba, Canada:

• Harvey Schipper, MD, FRCPC – Department of Medicine and Pharmacology, Faculty of Medicine, University of Manitoba; Director, WHO Collaborating Centre for Quality of Life in Cancer Care, Winnipeg, Canada.
• J. Clinch, MSc – Biostatistician, Department of Medicine and Clinical Epidemiology Unit, St. Boniface General Hospital, Winnipeg, Canada.
• A. McMurray, RN – Oncology Research Coordinator, St. Boniface General Hospital, Winnipeg, Canada.
• M. Levitt, MD, FRCPC – Department of Medicine and Medical Oncology, University of Manitoba, Winnipeg, Canada.

Purpose

The primary clinical and psychometric objective of the Functional Living Index – Cancer is to quantify the overall functional cost of malignant disease and its antineoplastic therapeutics from the direct viewpoint of the patient. Prior to the early 1980s, oncological assessment was overwhelmingly dominated by objective biomedical end-points: tumor volumetric response, disease-free progression intervals, toxic death rates, and overall survival duration. Functional capability was gauged almost exclusively via physician-rated indices, such as the Karnofsky Performance Status (KPS) or the Eastern Cooperative Oncology Group (ECOG) scale. While these clinical rubrics correlate well with physiological deterioration and immediate prognosis, they systematically underestimate affective distress, pain disruption, existential fear, interpersonal alienation, and subtle somatic toxicities experienced during chemotherapy, biological therapy, and radiation therapy.

Recognizing this critical discrepancy, Schipper and colleagues (1984) engineered the FLIC as a brief, self-administered questionnaire capable of being completed in clinical waiting rooms or inpatient settings within 5 to 10 minutes, thereby minimizing patient cognitive and physical fatigue. The instrument was intentionally constructed to meet four rigorous criteria: (a) patient-centered completion without clinical intermediary bias; (b) disease specificity to malignant pathologies; (c) multidimensional breadth encompassing physical, emotional, social, and role functionality; and (d) responsiveness to therapeutic interventions and disease progression over time.

In clinical trials, the FLIC serves as a primary or secondary efficacy endpoint, determining whether a novel chemotherapy regimen, surgical procedure, or palliative intervention preserves or degrades patient functional state relative to standard care. In routine oncology practice, serial administration of the FLIC aids clinicians in detecting treatment-induced toxicities early (e.g., severe anticipatory nausea, depressive symptomatology, escalating pain), guiding timely referrals to psycho-oncology, physical therapy, social work, or palliative supportive services.

Psychological Construct

The psychological and clinical construct measured by the FLIC is Health-Related Quality of Life (HRQoL), operationalized as the subjective functional impact of cancer and its clinical management on daily living. The instrument operationalizes HRQoL not merely as the absence of somatic pathology, but as an integrated, multidimensional state of well-being across five central psychological and functional domains:

1. Physical Well-Being and Somatic Discomfort

This domain captures the individual’s baseline perception of somatic health, bodily vigor, and systemic discomfort. Unlike simple toxicological symptom checklists, this dimension focuses on the overall physical appraisal of the illness. Items 1 (“How well do you appear today?”), 12 (“How uncomfortable do you feel today?”), and 17 (“How well do you feel today?”) explore immediate somatic homeostasis. Furthermore, items 3 and 10 evaluate the specific contribution of cancer-induced pain or discomfort to the disruption of everyday life, distinguishing generalized physical weariness from neoplastic pain.

2. Psychological and Emotional Well-Being

Cancer diagnosis and treatment induce intense existential, affective, and cognitive strain. The FLIC systematically evaluates affective disturbance, existential anxiety, cognitive coping, and subjective distress. Key items quantify existential terror concerning disease trajectory (Item 5: “Rate the degree to which you are frightened of the future”), cognitive rumination (Item 20: “How much time do you spend thinking about your illness?”), affective despair (Item 14: “Rate how often you feel discouraged about your life”), explicit depressive mood (Item 22: “Most people experience some feelings of depression at times. Rate how often you feel these feelings”), and overall cognitive coping with daily stressors (Item 21).

3. Functional and Occupational Role Performance

This dimension measures the degree to which malignancy curtails the individual’s capacity to engage in domestic productivity, leisure, and occupational endeavors. Items assess the completion of routine domestic responsibilities (Item 8), domestic chore satisfaction and professional work adequacy (Item 13), independent instrumental activities of daily living (Item 16: “Do you feel well enough to make a meal or do minor household repairs today?”), and the preservation of recreational and leisure outlets (Item 19). Impairment in this domain directly correlates with loss of personal autonomy and behavioral self-efficacy.

4. Social and Family Interpersonal Dynamics

Oncological illness severely impacts social relational systems, frequently precipitating role reversals, financial strains, and interpersonal friction. The FLIC gauges social motivation, such as willingness to interact with friends (Item 4) and close relatives (Item 7). Concurrently, it captures the psychological burden of perceived burden: the subjective perception of hardship imposed personally on the patient (Item 9), interpersonal disruption inflicted upon loved ones (Item 11), and objective external hardship borne by family members (Item 15).

5. Disease- and Treatment-Specific Somatic Burden

Certain cardinal toxicities universally undermine functional living regardless of tumor histology. The FLIC incorporates dedicated items evaluating gastrointestinal toxicity—specifically nausea severity (Item 6) and the functional interference of nausea with routine daily activities (Item 18). Additionally, it addresses patient appraisal of medical management, quantifying therapeutic trust through Item 2 (“Rate your confidence in your prescribed course of treatment”), capturing hope and therapeutic alliance.

Theoretical Framework

The conceptual framework of the FLIC is rooted in the Biopsychosocial Model formulated by George Engel (1977), integrated with the Transactional Model of Stress and Coping established by Richard Lazarus and Susan Folkman (1984), and modern psychometric theories of functional disability.

The Biopsychosocial Oncology Paradigm

Engel posited that biological pathophysiology alone cannot explain clinical manifestations or treatment outcomes; psychological and social contexts profoundly modulate symptom expression and perceived disease severity. Harvey Schipper and his co-investigators utilized this framework to challenge the prevailing oncological reductionism of the late 20th century. Under the FLIC conceptual framework, a biological entity (e.g., metastatic pulmonary adenocarcinoma) generates cellular damage, but the lived experience of that disease is mediated by cognitive appraisal, affective coping mechanisms, social support networks, and environmental roles. Thus, two individuals with identical TNM stages and identical biochemical toxicity profiles may exhibit dramatically divergent HRQoL trajectories depending on their emotional resilience, familial stability, and functional coping resources.

Cognitive Appraisal and Illness Representation

Drawing upon the transactional theory of stress, the impact of cancer is determined by primary appraisal (evaluating the threat posed by the disease to one’s life, identity, and future) and secondary appraisal (evaluating available resources to manage the threat). The FLIC explicitly samples these cognitive processes through items assessing fear of the future, intrusive thoughts regarding illness, and perceived burden on family. When primary appraisals of threat consistently outstrip perceived coping resources, functional living degrades, resulting in elevated scores on FLIC distress indices.

Functional Status and Disability Theory

The FLIC operationalizes “functional living” through the lens of functional limitation models (such as those later formalized by the World Health Organization’s ICF framework). Impairments at the organ level (pain, nausea) progress to activity limitations (inability to complete household chores, cook meals, or enjoy recreational pursuits), which ultimately culminate in participation restrictions (social withdrawal, vocational disruption). The FLIC integrates these layers into a single continuum, measuring the patient’s net functional capacity within their daily environment.

Validity

The psychometric validity of the FLIC has been comprehensively evaluated across clinical oncology trials, observational registries, and comparative psychometric investigations worldwide.

Construct and Structural Validity

During its initial validation across two distinct clinical centers (Winnipeg and Toronto; $N = 283$), Schipper et al. (1984) established construct validity by demonstrating that the FLIC effectively differentiated between distinct patient strata. Patients undergoing aggressive, toxic combination chemotherapy scored significantly lower on the FLIC than outpatients on stable maintenance protocols or those in complete clinical remission. Furthermore, the scale demonstrated sensitive longitudinal trajectories: patients experiencing progressive disease showed monotonic decreases in total FLIC scores, whereas clinical responders showed stable or statistically significant increases ($p < .001$).

Convergent and Criterion Validity

Convergent validity has been established through cross-validation against established physiological, affective, and functional measures:

• Karnofsky Performance Scale (KPS): Schipper et al. (1984) demonstrated moderate to strong correlations ($r = .60$ to $.69$) between clinician-rated KPS and FLIC physical/functional subscales, confirming that while FLIC captures physician-observable functional degradation, it accounts for substantial additional subjective variance.
• Depression and Anxiety Measures: The FLIC psychological items and overall composite score exhibit robust negative correlations with the Beck Depression Inventory (BDI; $r = -.60$ to $-.72$) and the Spielberger State-Trait Anxiety Inventory (STAI; $r = -.55$ to $-.68$), validating its capacity to capture affective comorbidity (Morrow et al., 1992).
• EORTC QLQ-C30 and SF-36 Multitrait-Multimethod Analysis: In a rigorous comparative study by Kuenstner et al. (2002), the convergent validity of the FLIC was benchmarked against the EORTC QLQ-C30 and the Medical Outcomes Study SF-36. Correlational matrices revealed high convergent coefficients ($r > .70$) between corresponding physical functioning, emotional well-being, and gastrointestinal symptom dimensions, confirming that the FLIC accurately targets the universal constructs of modern oncology HRQoL instruments.

Predictive and Prognostic Validity

Multivariate survival analyses across multiple solid tumor cohorts (including advanced non-small cell lung cancer, colorectal carcinomas, and metastatic breast malignancies) indicate that baseline FLIC scores serve as an independent prognostic indicator of overall survival time. Even after statistically controlling for baseline tumor stage, histological grade, serum biomarkers, and ECOG performance score, each 10-point decrement in baseline FLIC composite score significantly elevates the hazard ratio for all-cause mortality, emphasizing the clinical importance of patient-reported functional integrity.

Reliability

The FLIC possesses robust psychometric reliability across diverse cancer populations, demonstrating high internal consistency, strong test–retest temporal stability, and low standard errors of measurement.

Internal Consistency

In the seminal psychometric derivation study by Schipper et al. (1984), overall internal consistency for the 22-item composite scale yielded a Cronbach’s alpha of $\alpha = .90$. Subsequent validation studies across diverse clinical settings have corroborated these estimates:

• Morrow, Lindke, and Black (1992) reported an overall Cronbach’s alpha of $\alpha = .89$ in a large heterogeneous sample of oncology outpatients ($N = 848$).
• Kuenstner et al. (2002) observed an internal consistency coefficient of $\alpha = .91$ in a cohort of cancer patients undergoing systemic radiotherapy and chemotherapy.
• Subscale reliability coefficients consistently meet acceptable criteria: Physical Functioning subscale ($\alpha = .82$ to $.87$), Psychological Distress ($\alpha = .78$ to $.85$), Social/Family Burden ($\alpha = .74$ to $.81$), and Nausea/Gastrointestinal Toxicity ($\alpha = .84$ to $.89$).

Test–Retest Reliability

Temporal stability of the FLIC was evaluated by Schipper et al. (1984) in stable cancer outpatients over a 24- to 48-hour retest interval, yielding Pearson product-moment correlation coefficients ranging from $r = .85$ to $.91$. Morrow et al. (1992) reaffirmed this reproducibility across a 7-day test–retest protocol in clinically stable patients, finding intraclass correlation coefficients (ICCs) exceeding $.83$. These findings verify that the FLIC is resistant to transient day-to-day noise while remaining sensitive to true clinical shifts in disease status.

Standard Error of Measurement

The standard error of measurement (SEM) for the FLIC total score has been established across clinical literature as approximately 4.5 to 5.2 points. Consequently, the minimum clinically important difference (MCID) is widely identified as a shift of approximately 6 to 8 points on the 22–154 total scale.

Factor Analysis

The latent structure of the FLIC has been rigorously scrutinized using both exploratory factor analysis (EFA) and confirmatory factor analysis (CFA), clarifying the underlying dimensionality of the instrument.

Exploratory Factor Analysis (EFA)

Schipper et al. (1984) initially conceptualized the instrument across four clinical domains. However, subsequent principal components analyses with orthogonal (Varimax) and oblique (Promax) rotations performed by Morrow, Lindke, and Black (1992) on large patient datasets revealed a distinct five-factor latent structure explaining approximately 58% to 64% of total score variance:

• Factor 1: Physical Well-Being and Role Functioning (Items 1, 8, 12, 13, 16, 17, 19). Characterized by high loadings ($lambda > .55$) on general physical state, household productivity, mobility, and self-care capability.
• Factor 2: Psychological and Emotional State (Items 5, 14, 20, 21, 22). Defined by substantial loadings on existential dread, frequency of depressive mood, discouragement, rumination on cancer, and everyday stress tolerance.
• Factor 3: Gastrointestinal/Nausea Symptoms (Items 6, 18). Distinct, highly specific factor capturing the physiological magnitude and functional disruption of nausea.
• Factor 4: Social Interaction and Interpersonal Willingness (Items 4, 7). Marked by loadings on motivation and willingness to spend time with personal friends and immediate family.
• Factor 5: Hardship and Disruptive Illness Burden (Items 9, 11, 15). Reflecting the broader burden of cancer on the patient and their immediate social and familial environment.

Confirmatory Factor Analysis (CFA) and Short Forms

Confirmatory factor analytic investigations have supported the five-factor oblique model over a strict unidimensional model. Standard fit indices typically demonstrate acceptable model fit: comparative fit index (CFI) > .91, Tucker-Lewis Index (TLI) > .90, and root mean square error of approximation (RMSEA) ≈ .058 to .065.

In response to factorial redundancy across certain items, Cheung et al. (2003) conducted structural analyses to establish the Quick-FLIC, an abbreviated 11-item derivative. Psychometric evaluation confirmed that the Quick-FLIC reproduced the latent factor dimensions of the full scale while maintaining strong structural reliability, providing a rapid screening alternative for severely compromised patients.

Instrument / Measurement Tool

The Functional Living Index – Cancer is a standardized, self-administered patient-reported outcome measure structured as follows:

• Test Type: Multidimensional Health-Related Quality of Life (HRQoL) assessment instrument.
• Target Population: Adult oncology patients (aged 18 and older) across any cancer diagnostic category, anatomical site, or disease stage.
• Administration Format: Self-administered; available in paper-and-pencil, computerized, and tablet formats. Completion time is approximately 5 to 10 minutes.
• Item Count: 22 items.
• Response Scale: 7-point visual analogue scale / numerical rating format with continuous linear spacing. Each item features tailored bipolar semantic anchors corresponding to frequency, severity, capability, or degree of disruption.
• Scoring Architecture:
  • Raw scores for each item range from 1 to 7.
  • Direct-Scored Items: Items 1, 2, 4, 5, 7, 9, 11, 13, 14, 17, 20, and 21 are scored directly as marked (where higher numbers reflect better functioning, greater confidence, or lower hardship/distress).
  • Reverse-Scored Items: Items 3, 6, 8, 10, 12, 15, 16, 18, 19, and 22 are inverted prior to cumulative scoring. The reverse-scoring conversion formula is:
    $$\text{Item}_{\text{reversed}} = 8 – \text{Item}_{\text{raw}}$$
  • Total Score Calculation: The global FLIC score is calculated as the sum of all 22 recoded items:
    $$\text{Total Score} = \sum_{i=1}^{22} \text{Item}_i$$
  • Score Range: Theoretical minimum of 22 (extreme functional impairment, profound distress) to a theoretical maximum of 154 (optimal functional living, superior quality of life).
  • Missing Data Rules: If fewer than 3 items (<15%) are missing, the mean score of the completed items within the respective domain may be imputed. If 3 or more items are omitted, the total FLIC composite score cannot be reliably calculated.

Permissions & Fee and Test Year

The Functional Living Index – Cancer was originally published in 1984 by Harvey Schipper and colleagues. The scale is in the public domain for academic, clinical, non-commercial research, and educational applications. No licensing fees or royalties are required for clinical study adoption or independent academic research; however, investigators must cite the original 1984 Journal of Clinical Oncology publication. Commercial pharmaceutical trial licensing or proprietary electronic reproductions may require administrative permissions through academic repositories or institutional representatives holding archival custody.

References

• Cheung, Y. B., Khoo, K. S., Wong, Z. W., Saw, H. P., Wee, J., & Schipper, H. (2003). Quick-FLIC: A short questionnaire for assessing quality of life of cancer patients. Acta Oncologica, 42(1), 36–42. https://doi.org/10.1080/02841860310005083
• Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine. Science, 196(4286), 129–136. https://doi.org/10.1126/science.847460
• Kuenstner, S., Langelotz, C., Budach, V., Possinger, K., Krause, B., & Sezer, O. (2002). The comparability of quality of life scores: A multitrait multimethod analysis of the EORTC QLQ-C30, SF-36 and FLIC questionnaires. European Journal of Cancer, 38(3), 339–348. https://doi.org/10.1016/S0959-8049(01)00375-3
• Lazarus, R. S., & Folkman, S. (1984). Stress, appraisal, and coping. Springer Publishing Company.
• McDowell, I. (2006). Measuring health: A guide to rating scales and questionnaires (3rd ed.). Oxford University Press. https://doi.org/10.1093/acprof:oso/9780195165678.001.0001
• Morrow, G. R., Lindke, J., & Black, P. (1992). Measurement of quality of life in patients: Psychometric analyses of the Functional Living Index-Cancer (FLIC). Quality of Life Research, 1(5), 287–296. https://doi.org/10.1007/BF00434942
• Schipper, H., Clinch, J., McMurray, A., & Levitt, M. (1984). Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: Development and validation. Journal of Clinical Oncology, 2(5), 472–483. https://doi.org/10.1200/JCO.1984.2.5.472
• Schipper, H., & Levitt, M. (1985). Measuring quality of life: Risks and benefits. Cancer Treatment Reports, 69(10), 1115–1123.

13. Items of the Scale (Questionnaire)